Oyama K, Raz I, Cahn A, et al. - Patients with type 2 diabetes mellitus (T2DM) and a higher BMI were more likely to be hospitalized for heart failure (HHF) and atrial fibrillation or flutter (AF/AFL) in the DECLARE–TIMI 58 trial. While relative risk reductions in cardiovascular (CV) and renal outcomes with dapagliflozin were constant across the BMI spectrum, absolute risk reductions in obesity-related events such as HHF and AF/AFL tended to be bigger in obese T2DM patients.

• Of the 17, 134 patients, 9.0% had a normal BMI, 31.5% were overweight, 32.4% were moderately obese, 17.2% were severely obese, and 9.8% were very severely obese.

• Findings suggested an association of higher BMI with a higher adjusted risk of HHF and AF/AFL.

• Dapagliflozin consistently reduced body weight by similar relative amounts across BMI categories.

• Although the relative risk reductions in CV and renal-specific composite outcomes with dapagliflozin did not differ significantly across the BMI range, obese individuals (BMI ≥ 30 kg/m ²) tended to have a greater absolute risk reduction in HHF and AF/AFL than non-obese patients.